Clinical Trials Logo

Recurrence clinical trials

View clinical trials related to Recurrence.

Filter by:

NCT ID: NCT06150222 Not yet recruiting - Recurrence Clinical Trials

Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study

Retro-COSMOS
Start date: November 30, 2023
Phase:
Study type: Observational

This multi centric international retrospective study aims to register patients with oligo metastatic and oligo recurrent cervical cancer. The study will register patients in planned period with an aim to analyse clinical outcomes with or without use of radiation in this setting.

NCT ID: NCT06148961 Not yet recruiting - Clinical trials for Excessive Gingival Display

Effect of Botox Before Modified Lip Repositioning Repositioning Only in Relapse of the Excessive Gingival Display Within One Year

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The growing interest of patients in esthetic procedures, as well as the development of less invasive protocols in dentistry, has promoted the development of treatment plans that include stability, harmony, and function in orofacial rehabilitation. Poor esthetics interfere with an individual's personal, social, and professional relationships and is an individual consideration that varies according to the patient's age, time, region, and culture concerning what is considered beautiful.

NCT ID: NCT06147960 Not yet recruiting - Cancer of Cervix Clinical Trials

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer

EPIcol
Start date: November 2023
Phase:
Study type: Observational

Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.

NCT ID: NCT06102707 Not yet recruiting - Clinical trials for Ovarian Cancer Recurrent

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Ovarian cancer is the most lethal gynecological malignancy, posing a serious threat to women's health worldwide.Platinum resistant ovarian cancer is the biggest challenge faced by gynecological oncologists.Exploring more effective treatment options and how to delay the recurrence of platinum resistant recurrent ovarian cancer remains a challenging issue in clinical treatment.The main goal of this trial is to evaluate the effectiveness and safety of fluzopril combined with apatinib in maintenance treatment of platinum resistant recurrent ovarian cancer patients by evaluating progression free survival (PFS).Fifty patients with advanced ovarian cancer who underwent platinum resistant recurrent chemotherapy and assessed no disease progression were enrolled in the study, and maintenance treatment was performed with fluzopril combined with apatinib.

NCT ID: NCT06098989 Not yet recruiting - Clinical trials for Atrial Fibrillation, Persistent

A Prospective Study of REPeat Ablation In Patients With Recurrent PERSistent Atrial Fibrillation: Pulmonary Vein Isolation vs. Adjunct Posterior Wall Isolation (REPAIR PERS-AF Study)

REPAIR PERS-AF
Start date: November 15, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate the best strategy for repeat ablation of recurrent persistent atrial fibrillation (AF) after previous persistent AF ablation involving pulmonary vein isolation (PVI) along. Patients with low voltage areas on the posterer wall will be randomized to PVI alone or the posterer wall isoaltion (PWI) in addition to PVI.

NCT ID: NCT06097975 Not yet recruiting - Clinical trials for Recurrent Glioblastoma

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma

NEO-GLITIPNI
Start date: January 1, 2024
Phase: Phase 1
Study type: Interventional

The goal of this phase I interventional study is to determine the safety and feasibility of the proposed investigational (neo-)adjuvant treatment regimen in patients with resectable reccurent glioblastoma. Participants will: - receive neo-adjuvant administration of intravenous immunotherapy - followed by a maximal safe neurosurgical resection - afterwards, immunotherapy will be injected into the brain tissue - followed by insertion of an Ommaya reservoir - postoperatively, administration of immunotherapy will be continued

NCT ID: NCT06090994 Not yet recruiting - Colorectal Cancer Clinical Trials

Prevention of Postoperative Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Standard Treatment

Start date: October 2023
Phase: Phase 4
Study type: Interventional

This study is a prospective, multicenter, and exploratory study aimed at evaluating the effectiveness of Huaier Granules in preventing postoperative recurrence and metastasis of colorectal cancer.

NCT ID: NCT06075238 Not yet recruiting - Leukemia, Lymphoid Clinical Trials

Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

Start date: October 1, 2023
Phase: Phase 2
Study type: Interventional

The goal of this phase I/II clinical trial is to test in relapsed or refractory acute lymphoblastic leukemia (R/R ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • The efficacy and safety of blinatumomab maintenance therapy in reducing the recurrence rate a in R/R ALL patients after allo-HSCT. Participants will take intravenous blinatumomab after allo-HSCT. The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.

NCT ID: NCT06070285 Not yet recruiting - Clinical trials for Recurrent Ovarian Cancer

Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients

Start date: October 2024
Phase:
Study type: Observational

Clinical trials, with a particular focus on recurrent ovarian cancer, play a crucial role in assessing the safety and efficacy of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to support their widespread adoption. By actively participating in recurrent ovarian cancer observational study serves pivotal role in expanding the boundaries of medical knowledge and advancing the quality of care provided to those enduring the same condition.

NCT ID: NCT06070272 Not yet recruiting - Clinical trials for Recurrent Prostate Cancer

Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients

Start date: October 2024
Phase:
Study type: Observational

Clinical studies, with a dedicated focus on recurrent prostate cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to endorse their broader utilization. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with recurrent prostate cancer.